TG2 Inhibitor Program
Idiopathic Pulmonary Fibrosis (IPF)
Key Facts
About Isterian Biotech
Isterian Biotech is a private, preclinical-stage biotech founded in 2018, targeting pathological protein crosslinking as a root cause of fibrosis and aging. The company's core technology involves developing selective inhibitors of transglutaminase 2 (TG2), an enzyme responsible for creating durable crosslinks that resist degradation and drive tissue stiffening and dysfunction. As a subsidiary of Cambrian Bio, Isterian leverages a 'PipeCo' model and over 35 years of collective TG2 research expertise to advance its lead program for idiopathic pulmonary fibrosis (IPF) via inhaled administration. The company operates pre-revenue and aims to address a significant unmet need in a fatal disease with limited treatment options.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-01 | Molecure | Phase II |
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| NLM-001 | Nelum Pharma | Phase 1 |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| Taladegib (ENV-101) | Endeavor BioMedicines | Phase 2b |
| CAL101 | Calluna Pharma | Phase 2 |
| NVP-13 | Velvio | Pre-clinical |
| LASN01 | Lassen Therapeutics | Preclinical |